Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06590805
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-04
Brief Title:
Electroacupoint for Diminutive Milk Production
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Ameliorative Potential of Electroacupoint for Diminutive Milk Production in Lactating Woman
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study was to reveal the effect of electroacupoint on scanty milk production in lactating women
Detailed Description:
Postnatal scanty milk secretion is a common complaint Some physical and medicinal therapies have been proposed to enhance milk production These therapies must be both successful and safe for both the mother and the child In many cases milk supply can be increased by frequent regular milk removal Medication to increase milk supply galactogogues such as domperidone
Domperidone has been linked to maternal adverse effects in galactogogue trials and cases reported to the Food and Drug Administration include dry mouth headache dizziness nausea abdominal cramping diarrhea palpitations malaise and shortness of breath Some of these were more frequent with dosages greater than with 30 mg daily Drug withdrawal symptoms consisting of insomnia anxiety and tachycardia were reported in a woman taking 80 mg of domperidone daily for 8 months as a galactogogue who abruptly tapered the dose over 3 days
Domperidone has been linked to maternal adverse effects in galactogogue trials and cases reported to the Food and Drug Administration include dry mouth headache dizziness nausea abdominal cramping diarrhea palpitations malaise and shortness of breath Some of these were more frequent with dosages greater than with 30 mg daily Drug withdrawal symptoms consisting of insomnia anxiety and tachycardia were reported in a woman taking 80 mg of domperidone daily for 8 months as a galactogogue who abruptly tapered the dose over 3 days
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None